|
 |
AloxiThis page contains recent news articles, when available, and an overview of Aloxi but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Aloxi (when available) Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. For the treatment of aausea and vomiting associated with cancer chemotherapy Mechanism Of Action: Palonosetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT3 receptors. News Articles on Palonosetron 2008-07-02 23:19:18 - www.companiesandmarkets.com adds new report ... - 02 Jul 2008 The company markets cancer and acute care related pharmaceutical products such as Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the US. PR-Inside.com (Pressemitteilung), Clinic Roundup - Jun 23, 2008 Calif., completed enrollment in a Phase III trial comparing APF530 (sustained-release granisetron) to Aloxi (palonosetron hydrochloride, Eisai Co. TMCnet AP Pharma completes enrolment in Phase III trial of APF530 - Jun 26, 2008 The trial is comparing the efficacy of APF530 (its sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset Polish Market, AP Pharma fills up clinical trial of nausea drug - Jun 23, 2008 The drug is being tested against Aloxi, a treatment for similar symptoms approved by the FDA in 2003. That drug is marketed by MGI Pharma Inc., Conde Nast Portfolio, AP Pharma Completes Enrollment in Phase 3 Trial of APF530 - Jun 23, 2008 ...sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic PR-Inside.com (Pressemitteilung), Enrollment Complete for Phase III Trial of Chemo Side-Effects Drug - Jun 25, 2008 ...enrollment for a Phase III study in chemotherapy-induced nausea and vomiting (CINV) comparing the efficacy of APF530 with the anti-nausea drug Aloxi. FDA news (subscription), AP Pharma completes enrollment in Phase III CINV trial - Jun 24, 2008 ...chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced Trading Markets (press release), AP Pharma Completes Enrollment In Phase 3 Trial Of APF530 - Jun 25, 2008 ...sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic Medical News Today (press release), APPA: Completes Enrollment for Ph 3 Trial of Chemotherapy-Induced ... - Jun 23, 2008 ...sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic Trading Markets (press release), Market Report -- In Play (WIRES) - Jun 23, 2008 ...the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic chemotherapy treatments. MSN Money Eisai's Commitment to Oncology Demonstrated by Clinical Data to be ... - May 15, 2008 Aloxi is approved by the US FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly PR Newswire (press release), Allon Therapeutics Releases First Quarter Operating Results - May 15, 2008 VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 15, 2008) - Allon Therapeutics Inc. (TSX:NPC) The Neuro Protection Company TM , reported today in its First Market Wire (press release) Relief Is Final Chemotherapy Session - Apr 20, 2008 Walston, who had taken a prescription anti-nausea pill an hour earlier, first received saline for hydration and then a dose of Aloxi, another anti-nausea The Ledger, Eisai and partners win FDA approval for Aloxi injection for ... - Mar 2, 2008 Aloxi, available in the US since 2003, is the first and only 5-hydroxytryptamine-3 (5-HT3) receptor antagonist approved by the FDA for the prevention of Forbes, FDA approves Aloxi injection for nausea and vomiting - Mar 3, 2008 The new indication is based on one double-blind Phase III study that evaluated the efficacy of three doses of Aloxi compared to placebo for the prevention Trading Markets (press release), UPDATE 1-Eisai nausea drug gets US additional use approval - Mar 3, 2008 T: Quote, Profile, Research) said on Monday US regulators approved nausea treatment Aloxi to prevent vomiting after surgery -- its first approval for a drug Reuters Eisai nausea drug gets US additional use approval - Mar 2, 2008 T: Quote, Profile, Research), Japan's fourth-largest drug maker, said on Monday US regulators had approved its nausea treatment Aloxi to be used to prevent Reuters Helsinn Healthcare SA Announces the Launch of Aloxi(R ... - Feb 11, 2008 Aloxi(R) is a patented second generation 5-HT3 antagonist, which is differentiated by its strength on initiation and the duration of its activity. ITNews, Maelor launches anti-emetic drug Aloxi in UK - Feb 11, 2008 LONDON (Thomson Financial) - Specialist hospital medicines company Maelor PLC said it has launched Aloxi, a new generation anti-emetic drug for treatment of Hemscott, ALSO NOTED: Thai FDA chief quits after one week; Congress asks FDA ... - Mar 4, 2008 Release > Eisai and its partners MGI Pharma and Helsinn Healthcare said the FDA gave the nod to their Aloxi injection to prevent post-operative nausea and FiercePharma, FDA Approves Palonosetron for Prevention of Postoperative Nausea ... - Mar 3, 2008 WOODCLIFF LAKE, NJ -- March 3, 2008 -- The US Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the DG News Market highlights for next week - Feb 29, 2008 PDUFA date for MGI Pharma's sNDA for Aloxi for Post-Operative Vomiting. Note that MGI was bought by Eisai Co., Ltd. (OTC: ESALY). BloggingStocks Eisai Passes Hurdle for MGI Buyout - Jan 17, 2008 MGI makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy side effects, and Dacogen, for the bone marrow disease myelodysplastic Houston Chronicle, Under the Weather - Jan 31, 2008 ...dropped $3.9 billion to buy mgi Pharma, a fast-growing maker of drugs used to treat cancer symptoms, like Aloxi for nausea and Gliadel for pain. Forbes, Notice of Correction to Notice of Conversion Right for Senior ... - Jan 7, 2008 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with FOX News MGI Pharma Buyout Clears US Antitrust Hurdle - Jan 17, 2008 MGI Pharma's products include Aloxi injection for the prevention of chemotherapy-induced nausea and vomiting, Dacogen injection for the treatment of RTT News, sNDA Submitted for Aloxi® - Nov 29, 2007 Aloxi is a 5-HT3 receptor antagonist. The sNDA has been submitted for oral administration of Aloxi, versus the already approved intravenous formulation. Cancer Consultants (press release), The MGI Deal Makes Sense - Dec 11, 2007 MGI's top drug is chemotherapy-induced nausea treatment Aloxi, which constituted the majority of MGI's $289 million in revenue for the first nine months of Motley Fool Eisai To Acquire MGI Pharma - Dec 16, 2007 MGI Pharma's Aloxi for chemotherapy-induced nausea could reach $750 million in peak sales. Through the acquisition, part of its "Dramatic Leap" business Chemical & Engineering News Eisai to pay $3.9 billion in cash for MGI Pharma - Dec 10, 2007 The company is best known for its anti-nausea chemotherapy drug, Aloxi, with annual sales of about $250 million. But Aloxi now faces generic competition, Minneapolis Star Tribune (subscription), Eisai Agrees to Buy MGI Pharma for $3.9 Billion (Update6) - Dec 10, 2007 MGI, based in Bloomington, Minnesota, sells Aloxi shots for chemotherapy-induced nausea; the Gliadel Wafer, a biodegradable wafer with a chemotherapy agent; Bloomberg Japanese drug maker Eisai to buy MGI Pharma of the United States ... - Dec 11, 2007 Revenue from Aloxi, MGI's best-selling drug, fell 5.8 percent in the third quarter, to $66.3 million. "Eisai will be able to overcome the sales decline when International Herald Tribune, Japanese Firms Eye US Biotechs - Dec 11, 2007 MGI sells Aloxi to ease chemotherapy nausea and Dacogen to treat myelodysplastic syndromes. MGI investors got a nice 20% bump in share price this morning Forbes, Japan's Eisai to buy US drug maker MGI Pharma - Dec 11, 2007 Among other drugs, MGI makes Aloxi, an injection to help prevent post-chemotherapy nausea and vomiting, and the Gliadel Wafer for brain cancer. Los Angeles Times, MGI Pharma Rises on Board's Announcement - Nov 29, 2007 The analyst noted that the company's flagship drug, Aloxi, is differentiated "but competes in a hotly contested market." Aloxi is designed to help prevent Houston Chronicle, $4 billion deal to buy Bloomington marketer of cancer and acute ... - Dec 10, 2007 The company is perhaps best known for Aloxi, a drug that battles chemotherapy-related nausea that has been battered recently by generic competition. Minneapolis Star Tribune (subscription), Eisai Grabs MGI In $3.9B Deal - Dec 10, 2007 ...the treatment of myelodysplastic syndrome, Gliadel wafers, used to treat brain tumors, and Aloxi, an anti-nausea medicine used by chemotherapy patients. TheStreet.com Eisai Gaining Cancer Portfolio In $3.9B MGI Acquisition - Dec 10, 2007 The MGI deal adds five more marketed cancer products to the mix: Aloxi (palonosetron hydrochloride), for chemotherapy-induced nausea and vomiting (CINV); BioWorld Online, Japan's Eisai to buy US MGI Pharma for $3.9 bn - Dec 10, 2007 MGI's products include Aloxi, a treatment to prevent chemotherapy-induced nausea; Gliadel Wafer, a drug delivery device in the treatment of brain cancer; Economic Times, Eisai Agrees to Buy MGI Pharma for $3.9 Billion (Update1) - Dec 10, 2007 Bloomington, Minnesota-based MGI is the maker of Aloxi shots for chemotherapy-induced nausea. The transaction will ``allow Eisai to significantly strengthen Bloomberg Japan's Eisai To Buy US-based MGI Pharma For About $3.9 Bln In ... - Dec 10, 2007 The company's products include Aloxi injection for the prevention of chemotherapy-induced nausea and vomiting, Dacogen injection for the treatment of RTT News, Emerging Markets Consulting, LLC.: Emerging Markets Consulting ... - Dec 11, 2007 Its products include Aloxi injection for the prevention of chemotherapy-induced nausea and vomiting (CINV); Dacogen for Injection, for the treatment of Trading Markets (press release), MGI's Turn for "Strategic Alternatives" - Nov 30, 2007 MGI's top drug, Aloxi, competes with genericized drugs in the market to treat chemotherapy-related side effects. Ii also has Dacogen, which the FDA approved Motley Fool MGI Pharma To Evaluate Possible Strategic Alternatives; Hires ... - Nov 29, 2007 Though sales of the company's Aloxi, which treats nausea caused by chemotherapy, declined to $66.3 million in the recent third quarter from $77.3 million in RTT News, Ahead of the Bell: MGI Pharma - Nov 30, 2007 The analyst said a buyer could pay $40 per share for MGI, since the company is not very expensive and has valuable drugs in Aloxi and Dacogen for cancer Houston Chronicle, MGI PHARMA Issues Statement - Nov 29, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride)Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with Reuters Eisai in deal to acquire MGI Pharma for $3.9 billion - Dec 10, 2007 MGI Pharma makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy nausea and vomiting. It also sells injectable Dacogen for the Medical Marketing and Media, Eisai Closes $3.9 Billion Deal with MGI Pharma - Dec 10, 2007 By Charlie Brett The Japanese drug company Eisai Co. announced on Monday the acquisition of MGI Pharma Inc. (whose products include treatments such as Aloxi eFluxMedia Japanese drugmaker deals for MGI Pharma - Dec 10, 2007 MGI Pharma makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy nausea and vomiting. The company reported 2006 sales of more than WKBT, Eisai of Japan to buy the USA's MGI Pharma for $3.9 billion - Dec 10, 2007 For its money, Eisai is acquiring Aloxi (palonosetron) for chemotherapy-induced nausea, Dacogen (decitabine) for the treatment of myelodysplastic syndromes Pharma Times (subscription), MGI Pharma hangs out 'for sale' sign - Nov 30, 2007 MGI Pharma markets oncology and acute care drugs including an injection medication called Aloxi, which combats nausea and vomiting for patients undergoing Trading Markets (press release), MGI PHARMA Announces Aquavan NDA Accepted for Review by US FDA - Dec 17, 2007 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine WELT ONLINE, Helsinn Will Present at the 26th Annual JP Morgan Healthcare ... - Dec 18, 2007 Helsinn's key products in the US are Aloxi(R) (palonosetron) distributed by MGI Pharma and Gelclair(R) distributed by EKR Therapeutics Inc., US. PR Newswire (press release), MGI Pharma on the block; shares spike - Nov 29, 2007 MGI Pharma markets oncology and acute care drugs including Aloxi, which combats nausea and vomiting in patients undergoing chemotherapy. Pioneer Press, Japanese Drug Maker to Buy MGI Pharma for $3.9 Billion - Dec 10, 2007 MGI Pharma makes Aloxi, an injection for cancer patients to help prevent nausea and vomiting after chemotherapy. It also sells injectable Dacogen to treat New York Times, MGI Pharma Hits New High on Eisai Buyout - Dec 10, 2007 He said risks to that price target include clinical and regulatory risks as well as the potential that MGI's key medicines, anti-nausea drug Aloxi and Motley Fool Eisai To Buy Cancer-Drug Maker - Dec 10, 2007 MGI makes drugs like Aloxi, which is used to prevent chemotherapy-induced nausea, and Hexalen, which is used to treat ovarian cancer. Forbes, Stocks in the Spotlight Monday - Dec 10, 2007 ..."We are impressed with MGI's ability to fetch such a premium in light of [antinausea medication] Aloxi's rather finite patent life, an increasingly Barron's BIOTECH STOCKS Hematology drugmakers rise on buyout news, drug data - Dec 10, 2007 The drugmaker also makes Aloxi, which treats nausea associated with chemotherapy, and the chemotherapy product Gliadel. , , ) shares jumped 10% to $16.55. MarketWatch M&A Monday: MGI Pharma - Dec 10, 2007 MGI's drugs include Aloxi, which treats nausea caused by chemotherapy, and the cancer drug Dacogen. Shares rose $6.63, or 19.8 percent, to $40.08 in morning Forbes, Eisai to Acquire MGI PHARMA for $41 Per Share in an All Cash ... - Dec 10, 2007 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine WELT ONLINE, Mergers & Acquisitions - A Weekly Recap [MOGN] - Dec 14, 2007 MGI Pharma's major products include Aloxi shots for chemotherapy-induced nausea, the Gliadel Wafer containing a chemotherapy agent and Hexalen for treating RTT News, Thursday's Health Winners & Losers - Nov 29, 2007 ...the rumored prospective buyers of the company, whose products include blood-disorder drug Dacogen and chemotherapy-induced nausea preventive Aloxi. TheStreet.com Vodafone wins Qatar's 2nd mobile license - Dec 11, 2007 That's 23 percent more than MGI's closing price of Dec. 7. MGI, based in Bloomington, Minnesota, sells Aloxi shots for chemotherapy- induced nausea. Turkish Daily News (subscription), Eisai to buy MGI Pharma for $3.9B - Dec 10, 2007 MGI's drug Dacogen, for treatment of a group of blood disorders known as myelodysplastic syndromes, as well as Aloxi, for chemotherapy-induced nausea. NJ Blog, Eisai to Acquire MGI for $3.9 Billion - Dec 10, 2007 Earlier, there was a 5.8 percent drop in sales of Aloxi, the biggest selling drug at MGI during Q3 this year. Sales during this quarter dropped to $66.3 The Money Times, Eisai continues biologics push with $3.9bn MGI Pharma buy - Dec 10, 2007 MGI currently has three oncology and acute care products on the market: Aloxi (palonosetron hydrochloride), a treatment to prevent chemotherapy-induced DrugResearcher.com, Brand Names/Synonyms: Aloxi is also known by the following brand names and/or synonymsAloxi; Onicit; Palonosetron; Raloxifene Drug Category: Aloxi is categorized under the following by the FDA: Antiemetics; ATC:A04AA Dosage Forms: Not Available Absorption: Not Available Interactions: -->Interactions for Palonosetron: Palonosetron is eliminated from the body through both renal excretion and metabolic pathways. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low. Chemical IUPAC Name: Not Available : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |